Kypolis Onyx Pharmaceuticals Carfilzomib Injection
Get Latest Price
Manufacturer | Onyx Pharmaceuticals |
Brand | Kypolis |
Strength | 60 mg |
Packaging Size | 1 Vial |
Composition | Carfilzomib |
KYPROLIS is shown for the treatment of patients with different myeloma who have received somewhere around two earlier treatments including bortezomib and an immunomodulatory operator and have exhibited malady movement on or inside 60 days of fulfilment of the last treatment. KYPROLIS (carfilzomib) for Injection should be directed under the supervision of a certified doctor experienced in the employment of cancer chemotherapeutic operators.
Uses:
- KYPROLIS is a proteasome inhibitor shown for the treatment of patients with various myeloma who have received no less than two earlier treatments including bortezomib and an immunomodulatory operator and have exhibited illness movement on or inside 60 days of fruition of the last treatment.
Side Effects:
- Fever
* Fatigue
* Clogging
* Sickness
* Diarrhoea
* Shortness of breath
* Swelling of the limits
* Low platelet tally and blood platelet levels
Uses:
- KYPROLIS is a proteasome inhibitor shown for the treatment of patients with various myeloma who have received no less than two earlier treatments including bortezomib and an immunomodulatory operator and have exhibited illness movement on or inside 60 days of fruition of the last treatment.
Side Effects:
- Fever
* Fatigue
* Clogging
* Sickness
* Diarrhoea
* Shortness of breath
* Swelling of the limits
* Low platelet tally and blood platelet levels
Exports To: Japan | Brazil | Singapore | Slovakia | Bulgaria
View Complete Details
Get Latest PriceRequest a quote
G M Global
Mumbai, Maharashtra
4/5 (173)
★★★★★
★★★★★
GST- 27AAQFG0225P1Z0
Verified Supplier
Wholesale Trader
View Mobile Number
46% Response RateContact Supplier
Product Details
Company Details
Product Specification
Manufacturer | Onyx Pharmaceuticals |
Brand | Kypolis |
Strength | 60 mg |
Packaging Size | 1 Vial |
Composition | Carfilzomib |
Product Description
KYPROLIS is shown for the treatment of patients with different myeloma who have received somewhere around two earlier treatments including bortezomib and an immunomodulatory operator and have exhibited malady movement on or inside 60 days of fulfilment of the last treatment. KYPROLIS (carfilzomib) for Injection should be directed under the supervision of a certified doctor experienced in the employment of cancer chemotherapeutic operators.
Uses:
- KYPROLIS is a proteasome inhibitor shown for the treatment of patients with various myeloma who have received no less than two earlier treatments including bortezomib and an immunomodulatory operator and have exhibited illness movement on or inside 60 days of fruition of the last treatment.
Side Effects:
- Fever
- Fatigue
- Clogging
- Sickness
- Diarrhoea
- Shortness of breath
- Swelling of the limits
- Low platelet tally and blood platelet levels
Interested in this product?Get Latest Price from the seller
Contact Seller
About the Company
Year of Establishment2017
Legal Status of FirmPartnership Firm
Nature of BusinessWholesale Trader
Number of Employees11 To 25 People
Annual TurnoverUpto Rs. 50 Lakh
IndiaMART Member SinceMar 2019
GST27AAQFG0225P1Z0
Import Export Code (IEC)03169*****
Exports to Japan | Brazil | Singapore | Slovakia | Bulgaria
Seller Contact Details
Kasturi
3rd Floor Gala No.330/331 Western Express Highway Blue Rose Industrial Premises Cooperative Society, Mumbai - 400066, Maharashtra, India
Get DirectionsView Mobile No.
Send SMS
Send Email